Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted stock options to six new employees to purchase an aggregate 176,150 shares of common stock, effective June 1, 2026, under its 2022 Inducement Plan.
Options have a 10-year term, a $12.71 exercise price, and four-year vesting, in line with Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
OLMA was down 3.64% with several biotech peers also lower: ARVN -5.04%, BCAX -4.05%, VSTM -9.5%, SAGE -0.69%, while ORKA +1.56%. This points to broader sector softness rather than company‑specific momentum tied to the inducement grants.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 26 | Clinical collaboration | Positive | -0.9% | Bayer collaboration to study OP-3136 plus NUBEQA in mCRPC. |
| May 21 | Clinical data update | Positive | -2.7% | Initial Phase 1 OP-3136 data showing tolerability and anti-tumor activity. |
| May 19 | Conference participation | Positive | +4.1% | Announcement of three upcoming investor healthcare conference appearances. |
| May 12 | Earnings results | Negative | -6.0% | Larger quarterly net loss despite substantial cash and outlined milestones. |
| May 04 | Inducement grants | Neutral | +0.1% | Inducement stock options for five new employees under 2022 Inducement Plan. |
Recent clinically focused and collaboration news with positive implications often saw negative next-day moves, while a conference participation update and routine inducement grants had flat-to-positive reactions.
Over the last month, Olema has highlighted multiple milestones. A May 26, 2026 collaboration with Bayer on OP-3136 and encouraging Phase 1 data on May 21 both carried positive clinical narratives but were followed by modest declines. Investor conference participation on May 19 saw a 4.08% gain. First-quarter 2026 earnings on May 12 combined a larger net loss with a strong cash position and led to a -5.99% move. Similar inducement grants on May 4 saw little price impact.
Market Pulse Summary
This announcement details standard inducement stock option grants for six new employees, covering 176,150 shares at an exercise price of $12.71 with a four-year vesting schedule. It follows a similar inducement grant disclosed on May 4, 2026. In the broader context, Olema recently reported larger R&D-driven losses and multiple OP-3136 clinical updates. Investors may monitor how ongoing trial milestones and capital deployment interact with continued use of equity-based compensation.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective as of June 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
